DPP4 and coronary artery disorder: Of the diabetic subjects without CAD 47.0% was on treatment with sulphonylurea, 69.7% on metformin, 13.6% on glitazones, 3.0% on acarbose, 1.5% on megltitinides, 4.5% on DPP-4 inhibitors, and 44.6% on insulin.